A first definition of a pharmacophore for the serotonin reuptake inhibitors was carried out by consideringa three-dimensional model which correlates the chemical structures of series of reuptake inhibitors withtheir biological affinities. A molecular design was described by analyzing two different 3D serotoninpharmacophores. This successful approach enabled us to consider the design of new serotonin ligands bythe same method.